Analysts have been eager to weigh in on the Healthcare sector with new ratings on Syndax Pharmaceuticals (SNDX – Research Report) and Kodiak Sciences (KOD – Research Report).
Syndax Pharmaceuticals (SNDX)
Barclays analyst Peter Lawson reiterated a Buy rating on Syndax Pharmaceuticals yesterday and set a price target of $31.00. The company’s shares closed last Monday at $21.77.
According to TipRanks.com, Lawson is a 3-star analyst with an average return of
Syndax Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $34.50, representing a 50.0% upside. In a report issued on July 10, Guggenheim also initiated coverage with a Buy rating on the stock with a $40.00 price target.
See the top stocks recommended by analysts >>
Kodiak Sciences (KOD)
Barclays analyst Gena Wang reiterated a Sell rating on Kodiak Sciences yesterday and set a price target of $2.00. The company’s shares closed last Monday at $3.95.
According to TipRanks.com, Wang is a 5-star analyst with an average return of
Currently, the analyst consensus on Kodiak Sciences is a Moderate Sell with an average price target of $4.50, a 48.5% upside from current levels. In a report released yesterday, J.P. Morgan also downgraded the stock to Sell.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SNDX:
